Researchers at the RIKEN Center for Developmental Biology will treat the first patient in its clinical trial testing an induced pluripotent stem cell-based treatment for age-related macular degeneration.
First, the genetically engineered cells became CD8+ killer T cells that wiped out his leukemia. Then they transformed into a stable population of CD4+ helper T cells that continue to circulate in his body.